Income Statement Ion Beam Applications, SA
Equities
IBAB
BE0003766806
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.48 EUR | +2.74% |
|
+0.60% | +0.45% |
Feb. 07 | Ion Beam Applications, Framatome Partner to Produce Cancer Therapy Radioisotope | MT |
Feb. 07 | Framatome, IBA To Partner To Develop An Astatine-211 Cyclotron Network | RE |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 283M | 312M | 313M | 361M | 429M | |||||
Total Revenues | 283M | 312M | 313M | 361M | 429M | |||||
Cost of Goods Sold, Total | 189M | 176M | 205M | 235M | 294M | |||||
Gross Profit | 93.14M | 136M | 108M | 127M | 134M | |||||
Selling General & Admin Expenses, Total | 61.92M | 61.07M | 59.17M | 73.88M | 80.1M | |||||
Stock-Based Compensation (IS) | - | 125K | 844K | 941K | - | |||||
R&D Expenses | 31.13M | 33.12M | 34.01M | 41.84M | 47.92M | |||||
Other Operating Expenses | 485K | -55K | - | 656K | -1.13M | |||||
Other Operating Expenses, Total | 93.54M | 94.26M | 94.03M | 117M | 127M | |||||
Operating Income | -398K | 41.8M | 13.67M | 9.45M | 7.54M | |||||
Interest Expense, Total | -2.49M | -2.78M | -2.52M | -2.06M | -1.32M | |||||
Interest And Investment Income | 2.05M | 127K | 491K | 1.5M | 1.65M | |||||
Net Interest Expenses | -442K | -2.66M | -2.02M | -560K | 326K | |||||
Income (Loss) On Equity Invest. | -1.12M | -3.23M | -1.25M | 3K | -169K | |||||
Currency Exchange Gains (Loss) | 452K | -2.11M | 2.81M | 595K | -3.24M | |||||
Other Non Operating Income (Expenses) | -2.77M | 1.02M | -4.74M | -5.43M | -373K | |||||
EBT, Excl. Unusual Items | -4.28M | 34.82M | 8.45M | 4.06M | 4.09M | |||||
Restructuring Charges | -3.74M | -216K | -194K | - | -2.45M | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | 16.51M | -91K | - | - | - | |||||
Asset Writedown | - | -1.46M | - | - | - | |||||
Other Unusual Items | 2.27M | - | - | -4.49M | -1.96M | |||||
EBT, Incl. Unusual Items | 10.77M | 33.05M | 8.26M | -430K | -315K | |||||
Income Tax Expense | 3.16M | 1.13M | 4.38M | -6.49M | 8.8M | |||||
Earnings From Continuing Operations | 7.61M | 31.92M | 3.88M | 6.06M | -9.11M | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 7.61M | 31.92M | 3.88M | 6.06M | -9.11M | |||||
Net Income - (IS) | 7.61M | 31.92M | 3.88M | 6.06M | -9.11M | |||||
Net Income to Common Incl Extra Items | 7.61M | 31.92M | 3.88M | 6.06M | -9.11M | |||||
Net Income to Common Excl. Extra Items | 7.61M | 31.92M | 3.88M | 6.06M | -9.11M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.26 | 1.08 | 0.13 | 0.21 | -0.31 | |||||
Basic EPS - Continuing Operations | 0.26 | 1.08 | 0.13 | 0.21 | -0.31 | |||||
Basic Weighted Average Shares Outstanding | 29.45M | 29.63M | 29.42M | 29.14M | 29.13M | |||||
Net EPS - Diluted | 0.26 | 1.07 | 0.13 | 0.2 | -0.31 | |||||
Diluted EPS - Continuing Operations | 0.26 | 1.07 | 0.13 | 0.2 | -0.31 | |||||
Diluted Weighted Average Shares Outstanding | 29.49M | 29.71M | 30.16M | 30.18M | 29.13M | |||||
Normalized Basic EPS | -0.09 | 0.73 | 0.18 | 0.09 | 0.09 | |||||
Normalized Diluted EPS | -0.09 | 0.73 | 0.18 | 0.08 | 0.09 | |||||
Dividend Per Share | 0.08 | 0.2 | 0.19 | 0.21 | 0.17 | |||||
Payout Ratio | - | 7.06 | 149.14 | 92.11 | -67.19 | |||||
Supplemental Items | ||||||||||
EBITDA | 3.4M | 47M | 17.14M | 13.04M | 11.17M | |||||
EBITA | 365K | 43.26M | 13.67M | 9.78M | 7.8M | |||||
EBIT | -398K | 41.8M | 13.67M | 9.45M | 7.54M | |||||
EBITDAR | 3.97M | 47.34M | 17.52M | 13.44M | 11.72M | |||||
Total Revenues (As Reported) | - | - | 313M | 361M | 429M | |||||
Effective Tax Rate - (Ratio) | 29.31 | 3.43 | 53.01 | 1.51K | -2.79K | |||||
Total Current Taxes | 3.04M | 2.59M | 5.27M | 4.76M | 6.9M | |||||
Total Deferred Taxes | 111K | -1.46M | -890K | -11.24M | 1.9M | |||||
Normalized Net Income | -2.67M | 21.76M | 5.28M | 2.54M | 2.56M | |||||
Interest on Long-Term Debt | 589K | 579K | 645K | 776K | 589K | |||||
Non-Cash Pension Expense | 88K | 69K | 41K | 59K | 56K | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 24.5M | 19.28M | 19.34M | 24.79M | 26.28M | |||||
General and Administrative Expenses | 37.41M | 41.79M | 39.83M | 49.09M | 53.82M | |||||
Research And Development Expense From Footnotes | 33.22M | 35.02M | 35.4M | 44.2M | 51.3M | |||||
Net Rental Expense, Total | 568K | 347K | 375K | 394K | 550K | |||||
Imputed Operating Lease Interest Expense | 135K | 101K | 97.33K | 118K | 141K | |||||
Imputed Operating Lease Depreciation | 433K | 246K | 278K | 276K | 409K | |||||
Stock-Based Comp., Other (Total) | - | 125K | 844K | 941K | - | |||||
Total Stock-Based Compensation | - | 125K | 844K | 941K | - |